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Abstract
Secreted frizzle-related protein 2 (SFRP2), a modulator of Wnt-signaling, has recently been found
to be overexpressed in the vasculature of 85% of human breast tumors, however its role in
angiogenesis is unknown. We found that SFRP2 induced angiogenesis in the mouse Matrigel plug
assay and the chick chorioallantoic membrane assay. SFRP2 inhibited hypoxia induced endothelial
cell apoptosis, increased endothelial cell migration, and induced endothelial tube formation. The
canonical Wnt-pathway was not affected by SFRP2 in endothelial cells, however, a component of
the non-canonical Wnt/Ca++ pathway was affected by SFRP2, as demonstrated by an increase in
NFATc3 in the nuclear fraction of SFRP2-treated endothelial cells. Tacrolimus, a calcineurin
inhibitor which inhibits dephosphorylation of NFAT, inhibited SFRP2-induced endothelial tube
formation. Tacrolimus 3 mg/kg/daily inhibited the growth of SVR angiosarcoma xenografts in mice
by 46% (p=0.04). In conclusion, SFRP2 is a novel stimulator of angiogenesis that stimulates
angiogenesis via a calcineurin/NFAT pathway, and may be a favorable target for the inhibition of
angiogenesis in solid tumors.
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Angiogenesis is the growth of new capillary blood vessels, and is a critical component of solid
tumor growth(1). Limiting angiogenesis through blockade of vascular endothelial growth
factor (VEGF) has resulted in an increase in overall or progression-free survival in patients
with metastatic breast(2), colon(3), lung(4), and renal cell carcinoma(5). There is a need for
new angiogenesis inhibitors because not all tumors respond equally well to anti-VEGF therapy,
and most tumors eventually progress. Recognizing that tumor neovessels differ from normal
vasculature, we developed a novel method for immuno-laser capture microdissection coupled
with RNA amplification and genome-wide gene expression to profile tumor vasculature cells
from human breast tumors with comparison to normal breast samples(6). In our analysis, the
largest sample number to date of breast tumor vasculature, we identified 55 genes with greater
than 4-fold increased expression compared to normal. Secreted frizzle related protein 2
(SFRP2) mRNA was increased more than 6-fold in breast cancer endothelium, and as shown
by immunohistochemistry (IHC) 33/39 (85%) of breast tumors showed intense staining for
SFRP2 in the neovasculature. Importantly, SFRP2 was highly expressed in the vasculature of
luminal, Her2/neu, and basal tumors(6).
In our present study we evaluated the vascular expression of SFRP2 in angiosarcoma, colon
cancer, prostate cancer, lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell
carcinoma, and pancreatic cancer, and found that SFRP2 is strongly expressed in all tumors,
making SFRP2 a broad spectrum vascular target. Based on the expression of SFRP2 in vascular
endothelium, we hypothesize that SFRP2 stimulates angiogenesis. We sought to associate a
function with SFRP2 expression in endothelial cells using in vivo and in vitro angiogenesis
models.
Materials and Methods
Chick chorioallantoic membrane (CAM) assay
Fertilized chickens eggs (NC State University Chicken Research Farm) were incubated at 100°
F in an egg turner for 4 days and then cracked into sterile Petri dishes and incubated at 99°F
3%CO2 and 65% humidity. For application of drug onto the CAM, Whatman grade 1 filter
paper was cut into circles with a 6mm diameter paper punch and autoclaved, soaked in 1ml of
3.0mg/ml cortisone acetate in absolute ETOH and air dried for 60 min in laminar flow hood.
On day 8, 5 disks per egg were placed on outer third of CAM, 2–3 mm from a vessel. Control
0.1% BSA in PBS 7 μl was added to the discs for the control CAMs, and recombinant murine
SFRP2 (US Biologicals, Swampscott, MA) 100 ng/7 μl 0.1% BSA in PBS was added to the
disks for the treated CAMs (n=13 control disks and 23 SFRP2-treated disks). The CAMs were
evaluated under stereomicroscope on day 3 after disk placement. Pictures of the area around
the disk were taken with a Wild M-4 70 Macrosystem, and angiogenesis was quantified using
Metamorph Software with an angiogenesis module.
Mouse Matrigel plug angiogenesis assay
Mouse studies were approved by IACUC at UNC. The Matrigel plug assay was performed as
previously described(7). Female C57BL/6 mice (8 weeks old) were injected s.c. with 0.5 ml
of growth factor reduced basement membrane matrix (Matrigel) from BD Biosciences (San
Jose, CA) containing either mouse recombinant SFRP2 (800 ng/ml) with 30 U/ml heparin
(American Pharmaceutical Partners, Inc., Schaumburg, Illinois) or PBS with 30 U/ml heparin
for negative control, were injected s.c. on the back. Two to three Matrigel plugs were injected
per mouse. Seven days later the mice were sacrificed and the Matrigel plugs removed and
evaluated for angiogenesis by hemoglobin concentration with the Drabkin’s reagent as
previously described(8).
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The following antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA): β-catenin antibody (sc-59893) (1:500 dilution), NFATc1 (sc-7294) (1:500 dilution),
NFATc2 (sc-7296) (1:500 dilution), NFATc3 (sc- 8405) (1:250 dilution for Western blot, 1:100
dilution for IHC), H-Ras (sc-29) (1:500 dilution), FRP2 (sc-13940) (1:500 dilution for Western
blot, 1:100 dilution for IHC). The β-Tubulin loading control (ab6046) was purchased from
Abcam (Cambridge, MA.) and used in 1:1000 dilution. The following secondary antibodies
were purchased from GE Healthcare Bio-Sciences Corp. (Piscataway, NJ): ECL anti-mouse
IgG, HRP-Linked Whole antibody (NA931) and ECL anti-rabbit IgG, HRP-Linked Whole
antibody (NA934) with 1:100,000 dilution.
Cell culture
Human coronary artery endothelial cells (HCAEC) were purchased from Clonetics (San Diego,
CA). HCAEC were cultured in endothelial cell basal medium-2 (EGM-2) with BulletKit
growth supplements (Clonetics, San Diego, CA). Mouse myocardial endothelial cells (MEC)
from Robert Auerbach (University of Wisconsin) were grown in Low Glucose Dulbecco’s
Modified Eagle Medium (Gibco, Langley, OK) with 10% Fetal Bovine Serum (Hyclone,
Logan, UT). SVR angiosarcoma cells were obtained from Dr. Jack Arbiser (Emory University
Medical School) and cultured in Glucose Dulbecco’s Modified Eagle Medium 10% Fetal
Bovine Serum.
Endothelial cell apoptosis
HCAECs were used for apoptosis assays because we were not able to induce apoptosis with
hypoxia in the MEC cells. HCAEC were grown in 10-cm dishes (Becton Dickinson, Franklin
Lakes, NJ) with until 80% confluent. Media was replaced with EGM-2 without BulletKit
growth supplements and 70 pM or 700 pM of SFRP2 was added to the cells. The plate was
incubated in hypoxic conditions (37°C in a hypoxia chamber with an atmosphere of 5%
CO2/94% N2 with an oxygen level of 1.0%) for 36 hours. Apoptosis was measured by the
activity of cleaved Caspase 3 by using a caspase-specific fluorogenic substrate according to
the protocol for the Caspase 3 Assay Kit (Sigma, St. Louis, MO).
Endothelial cell proliferation assay
MECs (2000 cells/well) were seeded on a 96 well plate in media for 24 hrs. The cells were
quiesced in LG-DMEM with 0.1% FBS for 18 hours. Media was replaced with fresh LG-
DMEM with 0.5% FBS and the cells were treated in triplicate with PBS alone, or SFRP2 (7
nM – 7 pM). After 24, 48, or 72 h, 10 μl of the colorometric compound 3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) (5 mg/mL) was added to each
well and allowed to incubate for 4 h at 37°C. All but 25 μl of media in each well was removed
and 50 μl dimethyl sulfoxide (DMSO) was added. After 10 min at 37°C, the A540 was
measured using a microplate reader.
Scratch wound assay
MECs were plated at 10,000 cells/well into a 96 well plate and allowed to become confluent.
The cells were quiesced in DMEM without serum for 18 hours. The wound was formed using
a 1 ml pipette tip and a 0.7pM-700pM dose curve of mouse recombinant SFRP2 was added to
the wells. Migration distance was measured using a 1mm ocular ruler at time points between
16 and 32 hours.
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ECMatrix (Chemicon, Temecula, CA) was thawed, diluted and solidified into wells of a 96
well plate according to the manufactures instructions. MEC cells were seeded onto the matrix
at a concentration of 1×104 cells/well in 150 μl of DMEM with 10% FBS. A 7pM–7nM dose
curve of mouse recombinant SFRP2 was added to the wells and the plates were returned to 37°
C, 5% CO2 for 8 hours. Images were acquired using the Nikon Eclipse TS100 microscope at
4x magnification with a Nikon CoolPix 995 digital camera. Results were quantified by counting
the number of branch points.
For tacrolimus treatment experiments, MEC cells were treated as above with SFRP2 30nM
with and without tacrolimus (LC Laboratories, Woburn, MA) at concentrations ranging from
1μM–100μM for 8 hours and branch points were determined as described above. Inhibition of
SVR angiosarcoma tube formation by a polyclonal antibody to SFRP2 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, catalog # SC-13940) was performed after removing
sodium azide from the SFRP2 antibody using Zeba Desalt Spin Columns (Pierce
Biotechnology, Rockford, IL). SVR cells were plated onto ECMatrix as above and a dilution
curve of SFRP2 antibody (1:10-1:10,000) was added to the wells. Results were quantified by
counting the number of branch points.
SiRNA to SFRP2 in SVR angiosarcoma cells
SVR cells were transfected with 72 μM siRNA for Sfrp2 [FRP-2 siRNA (sc-40001, Santa Cruz
Biotechnology, Santa Cruz, CA)], which is a pool of 3 target-specific 20–25 nt siRNAs
designed to knock down SFRP2 gene expression. The three sequences are 5′-
GAGAUAACGUACAUCAACA-3′, 5′-CAAGCUGCAAUGCUAGUUU-3′, 5′-
CCAUGUCAGGCGAAUUGUU-3′. The sham siRNA (sc-36869, Santa Cruz Biotechnology,
Santa Cruz, CA) contains a scrambled sequence that does not lead to the specific degradation
of any known cellular mRNA. SVR cells were maintained in DMEM with 10% fetal calf serum.
After 72 h of transfection using Lipofectamine™ RNAiMAX Transfection reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol, cells were harvested for Western blot
analyses and tube formation assay. Cells were seeded for a 4 hour tube formation assay as
described above.
Western blot analyses
MECs were grown to 90% confluence followed by the change of media with and without mouse
recombinant SFRP2 (700 pM). Cells were incubated for 1, 2, 4, 8 and 16 hours with SFRP2.
MS1 and SVR cells were grown to 80–90% confluence. Nuclear and cytoplasmic proteins were
extracted by using NE-PER™ nuclear and cytoplasmic extraction reagent (Pierce
Biotechnology, Rockford, IL). The whole cell lysates were obtained using M-PER Mammalian
Protein Extract reagent (Pierce Biotechnology, Rockford, IL) as described in the
manufacturer’s manual. Protein concentration was measured using Bio-Rad Protein Assay at
OD595 (Bio-Rad Laboratories, Inc., Hercules, CA). Equal amount of protein (20 μg) was loaded
onto SDS-PAGE gels. Proteins were transferred to PVDF membrane, and Western blotting
was carried out using the proper primary antibody, with horseradish peroxidase (HRP)-
conjugated IgG as the secondary antibody. The ECL Advancetrade™substrate was used for
visualization (GE Healthcare Bio-Sciences Corp. Piscataway, NJ cat# RPN2135).
Immunohistochemistry
Immunohistochemistry with antibodies to SFRP2 was performed on paraffin embedded human
angiosarcoma, colon cancer, prostate cancer, lung cancer, ovarian cancer, pancreatic cancer,
hepatocellular carcinoma, and renal cell carcinoma as previously described(6).
Immunohistochemistry with antibodies to NFATc3 was performed on paraffin embedded
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human angiosarcoma. Tissues were sectioned at 8 μM, and 250ul of primary antibody (SFRP2
1:100 or NFATc3 1:100) was applied. A negative control without primary antibody was
performed. Two pathologists (CL and NO) scored each tissue section for SFRP2 and NFATc3
expression based on intensity of stain in endothelium and percent positive endothelial cells
staining.
Tumor Growth In Vivo
Mouse studies were approved by IACUC at Emory University. SVR cells (0.5×106) were
injected into the flank of 6-week-old nude male mice obtained from Charles River Breeding
Laboratories. Treatment was initiated on the day after inoculation. Mice received 3 mg/kg/
daily tacrolimus or vehicle control suspended in 20% Intralipid (Baxter Healthcare, Deerfield,
IL) in a total volume of 0.3 ml intraperitoneally (i.p.), and were treated daily for 19 days. Serial
caliper measurements of perpendicular diameters were used to calculate tumor volume using
the following formula: (shortest diameter)2 × (longest diameter) × 0.52.
Statistics
Statitistical differences for in vitro assays, Western blot analyses, CAM assay, and mouse
Matrigel plug assay were performed with a two-tailed Student’s t-test, as the data from these
experiments were normally distributed, with a p value < 0.05 being significant. For the in
vivo mouse tumor growth experiment, differences in tumor volume over time were analyzed
with a two way ANOVA. A P value of ≤ 0.05 indicated a statistically significant reduction in
tumor growth of the treated group compared to the control group.
Results
SFRP2 vascular expression in tumors
We performed IHC with antibodies to SFRP2 in seven different tumor types and evaluated the
intensity of staining in the vessels and the percent of endothelial staining. All tumors studies
(prostate cancer n=7, angiosarcoma n=9, hepatocellular carcinoma n=7, colon cancer n=8, clear
cell renal carcinoma n=8, lung cancer n=8, ovarian cancer n=8, and pancreatic cancer n=6) had
3+ vessel intensity staining in the tumor vasculature with the majority of endothelium staining
positive in most tumors (Fig. 1, Supplemental Fig. 1), demonstrating that SFRP2 is a vascular
target in a broad variety of tumors.
SFRP2 stimulates angiogenesis in vivo
We implanted SFRP2 (n=23) impregnated filter paper or control (n=13) on the developing
CAM on day 8. After 3 days, SFRP2 induced angiogenesis on the CAM with a statistically
significant increase in number of branch points (0.010), segments (0.013), tube percent area
covered (0.004), total tube area (0.008), and total tube length (0.008) (Fig. 2a). This observation
on the CAM indicates that SFRP2 is a stimulator of angiogenesis.
The angiogenic capacity of SFRP2 was confirmed by the mouse Matrigel plug assay. Seven
days after injection into mice, the control Matrigel plugs containing PBS and 30 U/ml heparin
and SFRP2 (800ng) + 30 U/ml heparin Matrigel containing plugs were removed. Evaluation
of the angiogenic response by measurement of hemoglobin content showed a 3.3 fold increase
in SFRP2 plugs compared with the vehicle control (n=25 SFRP2 plugs, n= 26 control plugs,
p=0.01, Fig. 2b–d).
SFRP2 promotes cellular processes required for angiogenesis
To explore the cellular mechanism through which SFRP2 promotes angiogenesis, we evaluated
the effects of SFRP2 on endothelial cell migration, proliferation, apoptosis, and tube formation;
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which are all important steps in the angiogenesis cascade(9). The effect of SFRP2 on the
migration properties of endothelial cells was evaluated using a scratch wound assay. At 16
hours, control mouse endothelial cells (MEC) migrated 480 μm ± 23, and SFRP2 (700pM)-
treated MEC cells migrated 680 μm ± 40, p < 0.01, n=3 per group (Fig. 3a).
SFRP2 (7pM–7nM) had no effect on MEC or HCAEC proliferation at 24, 48, or 72 hours (data
not shown). However, SFRP2 protected against hypoxia-induced HCAEC cell apoptosis.
Treatment with hypoxia alone in HCAEC cells resulted in a 6-fold increase in apoptosis
compared to cells in normoxia. Hypoxia does not induce apoptosis in MEC cells and therefore
the effect of SFRP2 on MEC cell apoptosis was not evaluable. Addition of SFRP2 (70pM and
700pM) to hypoxic HCAEC cells decreased apoptosis by 55% ± 9 (n=4 per group, p<0.02,
Fig. 3b).
MEC tube formation was induced by SFRP2 in a concentration-dependent manner at 8 hours
(p=0.0006 at 7nM, n=4 per group) (Fig. 3c). Taken together, these in vitro experiments
demonstrate that SFRP2 induces migration, anti-apoptosis, and tube formation, which are
important cellular processes necessary for new blood vessel formation.
To study whether loss of function of SFRP2 would inhibit tube formation we used a model of
a highly vascularized malignant endothelial tumor, the SVR angiosarcoma tumor model, which
was derived from the transfection of Ras into MS1 endothelial cells. MS1 cells were previously
generated by immortalizing murine endothelial cells by expressing the temperature-sensitive
large T antigen(10). Upon implantation into mice, these cells form dormant hemangiomas
(10). MS1 cells were then transfected with Ras (SVR), and this cell line forms angiosarcomas
when injected into nude mice(10).
We collected protein lysates from MS1 and SVR cells and, using Western blot analyses probing
for SFRP2, found that SFRP2 was increased in SVR cells compared to MS1 cells (Fig. 4a),
which correlated with H-RAS overexpression. We then transfected SVR angiosarcoma cells
with siRNA to SFRP2 or sham control and evaluated tube formation in a Matrigel assay. siRNA
trasnsfected SVR cells had 70% fewer branch points compared to sham transfected cells (sham
control =267 ± 33 branch points, siRNA SFRP2 transfected cells = 65 ± 10 branch points,
p=0.001, n=4 per group, Fig. 4b). We then treated SVR cells in a tube formation assay with a
polyclonal antibody to SFRP2 and found inhibition of SVR tube formation in a concentration
dependent manner (Fig. 4c).
Effects of SFRP2 on molecular signaling pathways in endothelial cells
To begin to elucidate the molecular mechanism of SFRP2 in angiogenesis, we first investigated
whether SFRP2 inhibited the canonical Wnt pathway, since SFRP2 has been reported to inhibit
this signaling pathway in other cell types(11). We compared protein levels of dephosphorylated
nuclear β-catenin in control and SFRP2 treated MEC cells. SFRP2 (30nM) decreased nuclear
β-catenin in SFRP2- stimulated endothelial cells at 1 hour (Supplementary Fig. 2). However,
at 700pM, which is the dose of SFRP2 that induced migration and tube formation in MEC
cells, there was no statistically significant change in nuclear β-catenin in the SFRP2- stimulated
endothelial cells at 1 hour (n=6 per group) (Fig. 5a), or at 2, 4, 8 and 16 hours (data not shown).
This suggests that although SFRP2 may inhibit the canonical-Wnt pathway in endothelial cells,
it is likely that the angiogenic effects of SFRP2 are being mediated through a non-canonical
pathway, because the canonical pathway was not inhibited at the lower concentrations of
SFRP2 which induce angiogenesis.
We next evaluated the role of the non-canonical Wnt/Ca++ pathway in SFRP2 induced
angiogenesis. When the non-canonical Wnt/Ca++ pathway is activated, calcineurin
dephosphorylates NFAT in the cytoplasm, allowing NFAT to translocate into the nucleus and
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act as a transcription factor(12). We found that NFATc3 was increased at 1 hour in the nuclear
fraction of SFRP2-treated MEC cells (Fig. 5b). There was no change in NFATc1 or NFATc2
in SFRP2-treated endothelial cells (data not shown). This suggests that SFRP2 is signaling
through the Wnt/Ca++ pathway and induces NFAT nuclear translocation in endothelial cells.
NFATc3 expression in human angiosarcoma
To correlate our in vitro finding of increased NFATc3 expression in SFRP2-treated endothelial
cells with in vivo data, we performed immunohistochemistry with antibodies to NFATc3 on
paraffin-embedded human angiosarcomas, and found that 6/8 tumors stained positive for
NFATc3 (Supplementary Fig. 3).
Tacrolimus inhibits SFRP2-induced tube formation and tumor growth in vivo
If SFRP2 stimulates angiogenesis via the calcineurin/NFAT pathway, then pharmacologic
inhibition of NFAT should inhibit SFRP2 induced angiogenesis. To test this hypothesis, we
studied whether tacrolimus would inhibit SFRP2 mediated angiogenesis. Tacrolimus (FK506)
binds to the immunophlin FKBP12. The FK506-FKBP12 complex associates with calcineurin
and inhibits its phosphatase activity, which inhibits nuclear translocation of NFAT(13).
Therefore we treated MEC cells in a tube formation assay with SFRP2 with and without
tacrolimus. Tacrolimus (1μM) inhibited SFRP2 induced MEC tube formation by 64%,
p=0.002, n=3 per group) (Fig. 3d). Tacrolimus was not cytotoxic to MEC cells, as only 5% of
tacrolimus-treated cells took up trypan blue dye (data not shown). This provides further support
for the role of NFAT in SFRP2 stimulated tube formation.
We then treated mice with SVR angiosarcoma xenografts with tacrolimus. Treatment with
tacrolimus (n = 12) at 3 mg/kg/day daily i.p. for 19 days was effective at suppressing the growth
of SVR angiosarcoma tumor in nude mice as compared with control (n = 12). Treatment with
tacrolimus reduced mean tumor volume by 46% at day 19 (589 ± 129 mm3 vs 315 ± 93
mm3, two-way ANOVA, p=0.04, Fig. 6a, b). There were no signs of toxicity (i.e., no diarrhea,
infection, lethargy, or weight loss) after 19 days of treatment.
Discussion
SFRP2 belongs to a large family of secreted frizzle-related proteins which are related to the
Wnt-signaling cascade, and has been previously implicated in cancer. Some studies suggest
that SFRP2 is an inhibitor of the Wnt-beta catenin pathway(11), and this data taken together
with reports of epigenetic inactivation of SFRP2 in breast cancer cell lines(14), oral squamous
cell carcinoma(15), and hepatocellular carcinoma(16) suggest that SFRP2 may be a tumor
suppresser gene. In contrast, several studies provide evidence that suggest that SFRP2 may
induce tumor growth. For example, SFRP2 has been found to be highly induced in canine
mammary gland tumors but not in normal mammary glands(17), and overexpression of
transfected SFRP2 in breast adenocarcinoma cells increased their resistance to apoptotic
signals (18). Additionally, SFRP2 has also been found to be produced by the majority of
malignant glioma cell lines, and SFRP2 overexpressing intracranial glioma xenografts were
significantly larger than xenografts consisting of control cells in nude mice(19). Although these
studies suggest contrasting views of the role for SFRP2 on tumor epithelium, no study to date
has evaluated the contribution of SFRP2 to angiogenesis.
We recently reported that SFRP2 is a novel tumor endothelial marker for breast cancer, and is
overexpressed in the endothelium of approximately 85% of human breast tumors, including
luminal A, basal, and Her2/neu subtypes(6). In this paper we now show that SFRP2 is expressed
in the vasculature of a wide variety of tumors, including angiosarcoma, renal cell carcinoma,
prostate cancer, lung cancer, ovarian cancer, pancreatic cancer and colon cancer, making
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SFRP2 a broad spectrum vascular target. Based on its overexpression in tumor endothelium,
we hypothesized that SFRP2 stimulates angiogenesis. We report that SFRP2 is a novel
stimulator of angiogenesis in vivo in the mouse Matrigel plug and CAM assays. SFRP2
modulates the cellular processes involved in angiogenesis, including endothelial cell migration,
tube formation, and protection against hypoxia-induced endothelial cell apoptosis, and is
required for angiosarcoma tube formation.
SFRP2 contains a cysteine-rich domain which is homologous to the putative Wnt binding
domain. The Wnt-signaling network influences biological processes ranging from
developmental cell fate to cell adhesion and apoptosis(11). Wnt proteins have been grouped
into two classes – canonical and noncanonical – on the basis of their activity in cell lines or in
vivo assays. The core of the Wnt pathway is the stability of beta-catenin. Although SFRPs have
been regarded as inhibitors of the canonical Wnt-beta catenin pathway(11), four recent studies
have shown that SFRP2 can act as a Wnt agonist rather than an antagonist. SFRP2 has been
found to increase nuclear beta-catenin levels in: 1) cardiomyocytes exposed to hypoxia and
treated with mouse recombinant SFRP2(20), 2) MCF7 cells with stable transfectants of SFRP2
(21), 3) mammary canine tumors with increased expression of SFRP2(17), and hypoxic adipose
tissue derived stem cells(22). Our study in endothelial cells show that at the dose of SFRP2
that induces angiogenesis, there is no change nuclear beta-catenin, suggesting that beta-catenin
is not responsible for the angiogenic actions of SFRP2. This led us to investigate whether the
angiogenic effects of SFRP2 are mediated through a noncanonical Wnt pathway.
Noncanonical Wnts activate other signaling pathways, such as the Wnt/Ca++ pathway(23) The
Wnt/Ca++ pathway is a beta-catenin-independent pathway for which signaling is mediated
through Wnt5a binding to the frizzled 5 transmembrane receptor, which leads to a transient
increases in cytoplasmic free calcium. This subsequently activates the phosphatase calcineurin.
Activated calcineurin dephosphorylates NFAT, which then translocates to from the cytoplasm
to the nucleus. The NFAT family consists of four members (NFATc1-c4), which exist as
transcriptionally inactive, cytosolic phosphoproteins(12). NFAT nuclear localization is
dependent on a dynamic import-export balance between the activity of the Ca++/calmodulin-
dependent phosphatase, calcineurin, and the activity of serine/threonine kinases(12). NFAT
cannot normally enter the nucleus until it is dephosphorylated, but can be activated by
calcineurin. Loss-of-function mutants have shown that NFAT signaling is crucial for normal
heart valve and vascular development during embryogenesis(12;24). Postnatally, this pathway
contributes to the regulation of cell growth, differentiation, and cell cycle progression in various
cell types, and there is increasing data supporting a critical role of NFAT in mediating
angiogenic responses(25;26). Importantly, NFAT activation was identified as a critical
component of VEGF-induced angiogenesis and linked to the induction of cyclooxygenase-2,
which is also a critical player in angiogenesis. NFAT is a crossing point for the endothelial cell
survival pathways initiated by proangiogenic VEGF and bFGF(26). Based on these
observations we hypothesized that SFRP2 activates NFAT in endothelial cells.
We found that NFATc3 protein was increased in the nucleus after treatment of endothelial cells
in vitro with SFRF2, and was present in human angiosarcomas that also expressed SFRP2.
Angiosarcoma is a biologically aggressive vascular malignancy with a high metastatic potential
and subsequent mortality. The 2- and 5-year overall survival for all patients with angiosarcoma
is 50 and 30%, respectively, with a median overall survival of 24 months(27). There is a
desperate need for novel therapies to improve survival in patients with this highly lethal disease,
and our findings suggest that targeting NFAT may be therapeutic strategy for angiosarcoma.
Tacrolimus is an immunosuppressive drug that binds to the immunophlin FKBP12. The
FK506-FKBP12 complex associates with calcineurin and inhibits its phosphatase activity,
which inhibits nuclear translocation of NFAT(13). We found that tacrolimus inhibited SFRP2
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induced tube formation in vitro and the growth of angiosarcoma xenografts in vivo, suggesting
that SFRP2 induces tube formation via a calcineurin-dependent NFAT pathway. Tacrolimus
has previously been shown to inhibit growth of a leukemia cell line in mice(28), and our report
is the first to our knowledge to demonstrate the tacrolimus inhibits angiogenesis in vitro and
solid tumor growth in vivo. The mechanism of tacrolimus needs to be distinguished from other
drugs used to prevent transplant rejection that are being studied in clinical trials for cancer,
such as sirolimus (rapomycin) and everolimus (RAD001, a deriviated of rapomycin). These
drugs have the same intracellular target as tacrolimus, FKBP12, but unlike tacrolimus these
drugs inhibit mTOR and have no effect on NFAT(29).
In summary, SFRP2, a secreted protein overexpressed in the vasculature of a large variety of
human tumors, is a novel angiogenesis stimulator. Our data suggests that SFRP2 mediates
angiogenesis via a calcineurin-dependent NFAT pathway, and that an inhibitor of the
calcineurin-NFAT pathway inhibit tumor growth. Based on its expression pattern and function,
SFRP2 and NFAT may be favorable targets for the inhibition of angiogenesis in solid tumors,
and direct tumor targets in angiosarcoma.
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SFRP2 protein is present in the endothelium in a wide variety tumor types by
immunohistochemistry. Paraffin-embedded sections of human tumors were stained with an
antibody to SFRP2 as described in Material and Methods. Pictures are taken at 600 ×
magnification.
Courtwright et al. Page 11














SFRP2 induces angiogenesis in vivo. (a) SFRP2 induces angiogenesis on the CAM. Filter disks
with and without SFRP2 100 nm were placed on the CAM on day 8 and angiogenesis was
quantitated as described in Materials and Methods. N= 13 control disks and n=23 SFRP2-
impregnated disks. SFRP2 induced statistically significant increase in number of branch points,
segments, tube percent area covered, and total tube length, as calculated with a two tailed t-
test. (b–d) SFRP2 induces angiogenesis in the mouse Matrigel plug assay. b) Control Matrigel
plug. c) SFRP2-impregnated matrigel plug. d) SFRP2 plugs had a 3.3 fold increase in
hemoglobin concentration compared to control plugs (n=25 SFRP2 plugs, n=26 control plugs,
*p=0.01, two-tailed t-test).
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Effects of SFRP2 on cellular processes involved in angiogenesis: (a) SFRP2 increases
endothelial cell migration in a wound scratch assay. The rate of wound closure is shown for
controls and increasing concentrations of mouse recombinant SFRP2. The values are the means
± SEM, n=3 for each concentration. SFRP2 increased MEC cell migration at low
concentrations ranging from 0.7pM–700pM. (b) SFRP2 inhibits hypoxia induced apoptosis in
HCAEC cells. HCAEC’s were incubated in a hypoxic chamber for 24 hours with and without
the addition of SFRP2. Relative Caspases 3 activity was measured as described in “Material
and Methods” Section. SFRP2 inhibited hypoxic induced apoptosis at 70pM and 700pM
(*p<0.02). (c) Mouse endothelial cell tube formation assay. SFRP2 induces endothelial tube
formation at 8 hours in a concentration-dependent manner. (d) Tacrolimus inhibits SFRP2
induced tube formation in mouse endothelial cells.
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SFRP2 is required for angiosarcoma tube formation. (a) Western blot analyses detects an
increase in SFRP2 protein in SVR angiosarcoma cell line compared to MS1 cells, which is
related to increased of H-ras protein in SVR cells. (b) siRNA to SFRP2 in SVR angiosarcoma
cells reduces tube formation compared to sham transfected controls, *p=0.001, n=4 per group.
(c) A polyclonal antibody to SFRP2 inhibits SVR tube formation in vitro.
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Western blot analysis for nuclear β-catenin and nuclear NFATc3 protein in mouse endothelial
cells treated with SFRP2. (a) There was no statistically significant change in nuclear β-catenin
after treatment with SFRP2 (700pM), the dose that effects endothelial cell tube formation,
migration, and apoptosis. (b) In contrast, nuclear NFATc3 was increased in SFRP2 treated
MEC cells at 1 hour, *p=0.01, n=3 per group.
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Tacrolimus inhibits the growth of SVR angiosarcoma xenograft in nude mice. Nude mice were
injected with 0.5 × 106 SVR tumor cells as described in “Material and Methods”. a) Tacrolimus
3 mg/kg (n=12) or control buffer (n=12) was injected i.p. daily starting the day after tumor
implantation. Treatment with tacrolimus reduced mean tumor volume by 46% at day 19 (589
± 129 mm3 vs 315 ± 93 mm3, two-way ANOVA, *p=0.04) b) Representative control mouse
tumor and representative tacrolimus treated mouse tumor on day 19 of treatment.
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